Cargando…
Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, the increasing therapeutic resistance caused by novel mutations or activated bypass pathways has...
Autores principales: | Sun, Ge, Mao, Longfei, Deng, Wenjing, Xu, Shuxiang, Zhao, Jie, Yang, Jianxue, Yao, Kaitai, Yuan, Miaomiao, Li, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776995/ https://www.ncbi.nlm.nih.gov/pubmed/35071184 http://dx.doi.org/10.3389/fchem.2021.789030 |
Ejemplares similares
-
Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole
por: Deng, Peng, et al.
Publicado: (2022) -
Discovery of a Series of Theophylline Derivatives Containing 1,2,3-Triazole for Treatment of Non-Small Cell Lung Cancer
por: Ye, Jiahui, et al.
Publicado: (2021) -
Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors
por: Hou, Xixi, et al.
Publicado: (2022) -
Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies
por: Xu, Gui-Qing, et al.
Publicado: (2022) -
Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
por: Mao, Long-fei, et al.
Publicado: (2020)